Kawthar Alghamdi

Kawthar Alghamdi

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2022 in Optical Materials
Verified
Journal Article
Closed access
MAMamoona Anwar
Mamoona Anwar
KAKawthar Alghamdi
Kawthar Alghamdi
SZSonia Zulfiqar
Sonia Zulfiqar
MWMuhammad Farooq Warsi
Muhammad Farooq Warsi
MWMuhammad Waqas
Muhammad Waqas
MHMurtaza Hasan
Murtaza Hasan

24 October 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
RSRaya Soltan
Raya Soltan
AAahlam alasiri
ahlam alasiri
MTMostafa N. Taha
Mostafa N. Taha
RERehab H. Abd El-Aleam
Rehab H. Abd El-Aleam
KAKawthar Alghamdi
Kawthar Alghamdi
Ahmed SayedAhmed Sayed
Ahmed Sayed
In the present study, norlobaridone (NBD) was isolated from Parmotrema and then evaluated as a new potent quorum sensing (QS) inhibitor against Pseudomonas aeruginosa biofilm development. This phenolic natural product was found to reduce P. aeruginosa biofilm formation (64.6% inhibition) and its related virulence factors, such as pyocyanin and rhamnolipids (% inhibition = 61.1% and 55%, respectively). In vitro assays inhibitory effects against a number of known LuxR-type receptors revealed that NBD was able to specifically block P. aeruginosa’s LasR in a dose-dependent manner. Further molecular studies (e.g., sedimentation velocity and thermal shift assays) demonstrated that NBD destabilized LasR upon binding and damaged its functional quaternary structure (i.e., the functional dimeric form). The use of modelling and molecular dynamics (MD) simulations also allowed us to further understand its interaction with LasR, and how this can disrupt its dimeric form. Finally, our findings show that NBD is a powerful and specific LasR antagonist that should be widely employed as a chemical probe in QS of P. aeruginosa, providing new insights into LasR antagonism processes. The new discoveries shed light on the mysterious world of LuxR-type QS in this key opportunistic pathogen.

Verified
Journal Article
Open access
PDF file
KAKawthar Alghamdi
Kawthar Alghamdi
RKRahaf Hashim Kassar
Rahaf Hashim Kassar
WFWesam Fouad Farrash
Wesam Fouad Farrash
AOAhmad A Obaid
Ahmad A Obaid
SIShakir Idris
Shakir Idris
AMAbdulrahman MUJALLI
Abdulrahman MUJALLI
Inflammatory Bowel Diseases (IBD), which encompass ulcerative colitis (UC) and Crohn’s disease (CD), are characterized by chronic inflammation and tissue damage of the gastrointestinal tract. This study aimed to uncover novel disease-gene signatures, dysregulated pathways, and the immune cell infiltration landscape of inflamed tissues. Eight publicly available transcriptomic datasets, including inflamed and non-inflamed tissues from CD and UC patients were analyzed. Common differentially expressed genes (DEGs) were identified through meta-analysis, revealing 180 DEGs. DEGs were implicated in leukocyte transendothelial migration, PI3K-Akt, chemokine, NOD-like receptors, TNF signaling pathways, and pathways in cancer. Protein–protein interaction network and cluster analysis identified 14 central IBD players, which were validated using eight external datasets. Disease module construction using the NeDRex platform identified nine out of 14 disease-associated genes (CYBB, RAC2, GNAI2, ITGA4, CYBA, NCF4, CPT1A, NCF2, and PCK1). Immune infiltration profile assessment revealed a significantly higher degree of infiltration of neutrophils, activated dendritic cells, plasma cells, mast cells (resting/activated), B cells (memory/naïve), regulatory T cells, and M0 and M1 macrophages in inflamed IBD tissue. Collectively, this study identified the immune infiltration profile and nine disease-associated genes as potential modulators of IBD pathogenesis, offering insights into disease molecular mechanisms, and highlighting potential disease modulators and immune cell dynamics.

1 September 2023 in Metabolites
Verified
Journal Article
Open access
PDF file
AMAbdulrahman MUJALLI
Abdulrahman MUJALLI
WFWesam Fouad Farrash
Wesam Fouad Farrash
KAKawthar Alghamdi
Kawthar Alghamdi
AOAhmad A Obaid
Ahmad A Obaid
Autoimmune diseases, characterized by the immune system’s loss of self-tolerance, lack definitive diagnostic tests, necessitating the search for reliable biomarkers. This systematic review aims to identify common metabolite changes across multiple autoimmune diseases. Following PRISMA guidelines, we conducted a systematic literature review by searching MEDLINE, ScienceDirect, Google Scholar, PubMed, and Scopus (Elsevier) using keywords “Metabolomics”, “Autoimmune diseases”, and “Metabolic changes”. Articles published in English up to March 2023 were included without a specific start date filter. Among 257 studies searched, 88 full-text articles met the inclusion criteria. The included articles were categorized based on analyzed biological fluids: 33 on serum, 21 on plasma, 15 on feces, 7 on urine, and 12 on other biological fluids. Each study presented different metabolites with indications of up-regulation or down-regulation when available. The current study’s findings suggest that amino acid metabolism may serve as a diagnostic biomarker for autoimmune diseases, particularly in systemic lupus erythematosus (SLE), multiple sclerosis (MS), and Crohn’s disease (CD). While other metabolic alterations were reported, it implies that autoimmune disorders trigger multi-metabolite changes rather than singular alterations. These shifts could be consequential outcomes of autoimmune disorders, representing a more complex interplay. Further studies are needed to validate the metabolomics findings associated with autoimmune diseases.

3 January 2026 in Journal of Sol-Gel Science and Technology
Verified
Journal Article
Closed access
PDF file
KAKawthar Alghamdi
Kawthar Alghamdi